Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

• Status: Withdrawn
• Trial end date: 2022-05-01

Summary

The goal of this clinical research study is to learn if fludarabine, cytarabine (ARA-C), and erwinase (also known as asparaginase [erwinia]) in combination can help to control relapsed or refractory hematologic malignancies. The safety of these drugs will also be studied.

• Phase: Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Jazz Pharmaceuticals
• Treatments: Asparaginase; Cytarabine; Fludarabine; Fludarabine phosphate; Vidarabine